The PRiME Study (Brain Cancer)
What is the Purpose of this Study?
If you, or your child, choose to join this study, you or your child will:
- Have a blood test for a common virus called cytomegalovirus (CMV)
- Have standard radiation therapy with temozolomide (a chemotherapy) before study procedures
- Have blood drawn
- Get a Tetanus-diphtheria (Td) vaccine shot (given in the leg)
- Get the study vaccine (PEP-CMV) every 2 weeks for the first 3 vaccines and then once a month
- Have a blood test for a common virus called cytomegalovirus (CMV)
- Have standard radiation therapy with temozolomide (a chemotherapy) before study procedures
- Have blood drawn
- Get a Tetanus-diphtheria (Td) vaccine shot (given in the leg)
- Get the study vaccine (PEP-CMV) every 2 weeks for the first 3 vaccines and then once a month
What is the Condition Being Studied?
Brain Cancer (World Health Organization Grade III or IV glioma or medulloblastoma)
Who Can Participate in this Study?
Children and adults, 3-35 years old with:
- Grade III or IV glioma that has progressed or recurred
- Medulloblastoma that has progressed or recurred
Age Group
Both
Participating Institutions
What is Involved?
We are doing this study to learn more about the study vaccine (PEP-CMV) and to understand if it helps the immune system fight brain cancer.
Study Details
Full Title
The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/malignant glioma
Principal Investigator
Protocol Number
IRB:
PRO00079843
NCT:
NCT03299309
ClinicalTrials.gov
View on ClinicalTrials.gov